Teclistamab
Modify Date: 2025-11-29 12:50:21
Teclistamab structure
|
Common Name | Teclistamab | ||
|---|---|---|---|---|
| CAS Number | 2119595-80-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TeclistamabTeclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM)[1]. |
| Name | Teclistamab |
|---|
| Description | Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM)[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Teclistamab (0.01-1000 nM, 48 h) 可以诱导 T 细胞介导的细胞毒性，在 H929 细胞中的 EC50 值为 0.15 nM，在MM.1R 细胞系中为 0.06 nM，在 RPMI 8226 细胞系中为 0.45 nM[1]。 Teclistamab (0.01-1000 nM, 48 h) 能以剂量依赖方式结合 CD138 +人 BM 单核细胞，并诱导人 BM 单核细胞的细胞毒性[1]。 |
| In Vivo | Teclistamab (i.v., 0.1-1 μg, once every 2 days) 在雌性 NSG（NOD/SCID/γc-/）小鼠 H929 细胞模型中具有大剂量的抗肿瘤活性[1]。 Animal Model: Female NSG mice infected with H929 cell lines[1] Dosage: 0.1 µg (0.005 mg/kg), 0.5 µg (0.025 mg/kg), or 1 µg (0.05 mg/kg) Administration: i.v., on days 0, 3, 5, 7, and 10 Result: Completely inhibited tumor growth at doses of 0.5 and 1 μg, while no inhibition of tumor growth was observed at a dose of 0.1 μg. |
| References |
| No Any Chemical & Physical Properties |